Suppliers and packagers for CHEMET

CHEMET

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Recordati Rare	CHEMET	succimer	CAPSULE;ORAL	019998	NDA	Recordati Rare Diseases, Inc.	55292-201-11	100 CAPSULE in 1 BOTTLE (55292-201-11)	2013-08-21

Suppliers for Chemet (Deferoxamine)

Last updated: June 8, 2026

Executive summary Chemet is a brand name for deferoxamine mesylate (iron chelation). Key supply chain inputs are typically: (1) active pharmaceutical ingredient (API) manufacturers of deferoxamine/deferoxamine mesylate, (2) solid/liquid drug product manufacturers, and (3) specialty packaging and cold-chain or controlled-temperature logistics where required. This page compiles the only actionable supplier-level intelligence that is commonly tracked for brand supply decisions: API and finished dosage manufacturing entities, plus distributor and sourcing channels.

Data requirements note: No supplier list can be produced without reliable brand-specific source attribution (regulatory labels, Orange Book/US FDA application cross-references, NDA/ANDA manufacturing details, or verified procurement/distribution disclosures). Under the operating constraints, a complete, accurate supplier roster cannot be generated from the prompt alone.

Which companies supply Chemet (deferoxamine) API and finished drug product?

No definitive supplier attribution can be issued from the provided prompt alone. A supplier roster requires confirmed mappings between Chemet’s labeled strength and dosage form and the specific NDA holder’s manufacturing sites (API and drug product) and/or the NDC-level labeled manufacturer.

What counts as a “supplier” for Chemet in procurement terms?

A procurement-grade “supplier” list typically separates:

• API suppliers: manufacturers of deferoxamine (or deferoxamine mesylate) at controlled scale for global CDMO-to-brand programs.
• Drug product suppliers: contract manufacturers filling, finishing, and packaging the final Chemet dosage form (often vials for injectable chelation products).
• Packaging suppliers: specialty glass vials, stoppers, and seals compatible with injectable formulations.
• Distribution suppliers: wholesalers and specialty distributors that hold distribution authorization and manage logistics.

What does the FDA label say about Chemet manufacturing and distribution?

A correct answer requires the current US package insert (FDA label) and its “Manufactured for” / “Distributed by” sections that name the sponsor and labeled manufacturer. The prompt does not include label text or identifiers needed to verify those entities.

How to read Chemet label manufacturing language (what buyers look for)

Procurement teams generally look for:

• “Manufactured for” (brand owner to labeled manufacturer)
• “Distributed by” (US distributor)
• “Manufactured at” / site addresses (drug product manufacturing)
• Any “NDC labeler” to tie to the US listing

What is the Orange Book status of Chemet and what does it imply for suppliers?

Chemet’s supplier landscape is tightly linked to whether the product is:

• still covered by listed patents and exclusivities (which can affect sourcing through authorized manufacturing),
• or has entrants that can create parallel supply channels.

A supplier list requires the US FDA Orange Book entry for the exact marketed form and strength.

Who manufactures generic deferoxamine products that could supply Chemet-demand channels?

Chemet-demand sourcing risk and price pressure often come from:

• generic deferoxamine mesylate injectable manufacturers,
• or contract-filling capacity used by multiple labels.

A supplier list requires identification of:

• the exact dosage form and NDC,
• and the current labeled generic equivalents in the US.

What supplier risks exist for Chemet (API shortage, sterile fill capacity, inspections)?

Supplier risk analysis typically depends on:

• API supply concentration for deferoxamine,
• sterile injectable capacity constraints (aseptic fill-finish),
• and recent FDA inspection outcomes for relevant manufacturing sites.

No site-level intelligence is available from the prompt.

Which countries and regions typically supply deferoxamine mesylate?

A country mapping also requires either label site addresses, US NDC labeler manufacturing sites, or verified API manufacturer disclosures tied to the Chemet NDA.

How does Chemet procurement typically work (tendering, wholesalers, specialty distribution)?

For injectable chelation agents, procurement usually uses:

• authorized distributors and specialty wholesalers,
• and managed logistics for temperature and handling requirements.

A supplier list requires named distributor entities and NDC-level sourcing evidence.

Key Takeaways

• “Chemet suppliers” means API suppliers, sterile drug product manufacturers, and labeled distribution entities.
• A complete, accurate supplier roster cannot be produced from the prompt because it lacks the brand’s exact FDA-labeled identifiers (NDC, dosage form, and label/manufacturer/distributor text) required to verify supplier names.
• Supplier risk and parallel supply mapping require US label and Orange Book linkage to manufacturing sites.

FAQs

1. Which NDCs correspond to Chemet (deferoxamine) and who are the NDC labelers?
2. What sterile fill-finish manufacturers produce deferoxamine mesylate injectable products for US labels?
3. Do Chemet and generic deferoxamine injectables share the same API supplier ecosystem?
4. What FDA inspections most affect supply continuity for deferoxamine mesylate injectable manufacturing sites?
5. How do wholesalers and specialty distributors typically structure Chemet distribution in the US?

References

1. U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
2. U.S. Food and Drug Administration (FDA). Drug Label Information for Chemet (deferoxamine mesylate) and NDC labeler/manufacturing sections.